Business, energy, technology, markets and global industry news from Business News Today

AstraZeneca

PharmaDeviceNews AstraZeneca
Datroway’s European Union approval expands first-line treatment options for patients with unresectable or metastatic triple-negative breast cancer who are not candidates for immunotherapy, following an overall survival benefit in the Phase 3 TROPION-Breast02 trial. Representative image.
Pharma & Biotech

Datroway EU approval expands first-line treatment options for metastatic triple-negative breast cancer

EU approval moves Datroway into first-line metastatic TNBC after TROPION-Breast02 showed survival gains, intensifying the TROP2 ADC race.

Read More
AstraZeneca’s investigational CLDN18.2 antibody-drug conjugate sonesitatug vedotin improved overall survival in a Phase 3 trial involving previously treated advanced gastric and gastroesophageal junction cancers, although the progression-free survival endpoint was not statistically significant. Representative image.
Pharma & Biotech

Sonesitatug vedotin Phase 3 survival win strengthens AstraZeneca’s gastric cancer ADC strategy

Read why AstraZeneca’s sonesitatug vedotin survival win in CLDN18.2-positive gastric cancer is tempered by a Phase 3 PFS miss.

Read More
Laboratory research into AbelZeta Pharma’s C-CAR031 armored GPC3 CAR-T therapy highlights the emerging potential and durability challenges of cellular treatment for advanced hepatocellular carcinoma. Representative image.
Pharma & Biotech

AbelZeta and AstraZeneca study identifies GPC3 loss as a potential C-CAR031 resistance mechanism

AbelZeta’s C-CAR031 study shows a 44.4% response rate in advanced liver cancer, but durability and resistance remain key tests.

Read More
Enhertu plus pertuzumab has received CHMP backing as a potential first-line treatment for HER2-positive metastatic breast cancer, bringing the combination closer to European Union authorization. Representative image.
Pharma & Biotech

Why Enhertu’s EU recommendation could end a decade of stability in first-line HER2 breast cancer treatment

EU regulators back Enhertu plus pertuzumab for first-line HER2-positive metastatic breast cancer, shifting focus to approval, safety and access.

Read More
Harbour BioMed’s antibody discovery platforms and global biopharma partnerships are supporting revenue growth and a seventh consecutive profitable half-year, although the company’s full interim results will determine the durability of its earnings momentum. Representative image.
Pharma & Biotech

Harbour BioMed’s revenue is climbing, but one profit number complicates the growth story

Harbour BioMed expects up to $67 million interim profit as antibody deals lift revenue, but margin trends will shape the next investor debate.

Read More
Avacta’s upcoming AVA6103 clinical data will test whether its sustained-release exatecan therapy can concentrate cancer treatment inside tumours while limiting systemic exposure. Representative image.
Features & Analysis

Avacta previews AVA6103 pharmacokinetic data as sustained-release cancer drug faces first human test

Avacta’s next AVA6103 data will test sustained exatecan release in cancer patients. Read what the FOCUS-01 results could mean for its platform.

Read More
Representative image: Laboratory researchers assess an oral blood disorder therapy as Nuvectis Pharma’s ciprocopan secures China approval for treatment-naive paroxysmal nocturnal hemoglobinuria.
Pharma & Biotech

Ciprocopan China approval gives PNH patients a new once-daily oral Factor B treatment option

Nuvectis Pharma’s ciprocopan wins China approval for PNH. Read how the once-daily Factor B drug could reshape the global treatment race.

Read More
Neurimmune’s cliramitug royalty sale to Royalty Pharma for up to $425 million supports funding for its research pipeline as the ATTR-CM antibody advances through Phase 3 development. Representative image.
Pharma & Biotech

Why Royalty Pharma is betting up to $425m on Neurimmune’s Phase 3 heart drug

Neurimmune sells part of its cliramitug royalty to Royalty Pharma for up to $425 million as the ATTR-CM antibody advances through Phase 3.

Read More
Representative image: Eplontersen’s Phase 3 CARDIO-TTRansform setback raises questions about AstraZeneca and Ionis Pharmaceuticals’ ATTR cardiomyopathy strategy.
Pharma & Biotech

Ionis Pharmaceuticals shares slide as eplontersen misses key heart disease endpoint

See why the CARDIO-TTRansform miss complicates eplontersen’s ATTR-CM path and tests gene silencing on top of stabilizer therapy.

Read More
Representative image: A pathology specialist reviews PTEN biomarker staining as NeoGenomics launches an FDA-approved companion diagnostic to identify prostate cancer patients who may be eligible for AstraZeneca’s Truqap.
Medical Devices & Diagnostics

How the NeoGenomics PTEN IHC test supports targeted prostate cancer treatment

NeoGenomics launches an FDA-approved PTEN IHC companion diagnostic to identify prostate cancer patients eligible for AstraZeneca’s Truqap.

Read More